Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05092048 | A Study for PRO of CML in Real Word(Case-Only) | unknown | — | 10,000 | xunaOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT04593745 | Intraocular Pressure in Children With Acute Lymphoblastic Leukemia (ALL) Treated With High Dose Steroids(ALL) | unknown | N/A | 100 | Rabin Medical CenterOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT05088330 | A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM | unknown | N/A | 76 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Oct 21, 2021 | clinicaltrials |
| NCT05084872 | Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients(HCQMa) | unknown | Phase 2 / Phase 3 | 30 | University Hospital, ToulouseOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT05080829 | Myeloid Mutations Register in R/R CML | unknown | N/A | 29 | Grupo Cooperativo de Hemopatías MalignasOTHER | 1 | Oct 18, 2021 | clinicaltrials |
| NCT04931875 | Total-body PET / CT in the Evaluation of Treatment and Prognosis of Lymphoma | unknown | — | 100 | RenJi HospitalOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT03505944 | Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma(VALERIA) | unknown | Phase 1 / Phase 2 | 59 | Nordic Lymphoma GroupNETWORK | 4 | Oct 13, 2021 | clinicaltrials |
| NCT05075655 | Endobronchial Diagnosis of Lymphoma(EnDol) | unknown | N/A | 33 | University Hospital, CaenOTHER | 1 | Oct 13, 2021 | clinicaltrials |
| NCT04320420 | Feasibility of an Adapted Physical Activity Program for Patients Treated With an Autograft (APA²)(APA²) | unknown | N/A | 57 | WepromOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT05066958 | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT | unknown | Phase 1 / Phase 2 | 20 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT03257241 | A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old(PALG-AML1/2016) | unknown | Phase 3 | 582 | Polish Adult Leukemia GroupOTHER | 2 | Oct 1, 2021 | clinicaltrials |
| NCT04037189 | Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia | unknown | — | 250 | Rabin Medical CenterOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT05024357 | A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL | unknown | N/A | 80 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT05026229 | A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL | unknown | N/A | 60 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT03887156 | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft(Predictor2) | unknown | Phase 2 / Phase 3 | 227 | Assistance Publique - Hôpitaux de ParisOTHER | 3 | Sep 28, 2021 | clinicaltrials |
| NCT04948788 | SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma | unknown | Phase 2 | 102 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 28, 2021 | clinicaltrials |
| NCT05059847 | Impact of Cross-training on Induction Treatment Response in Acute Lymphoblastic Leukemia Adults | unknown | N/A | 114 | Hospital General de MexicoOTHER_GOV | 1 | Sep 28, 2021 | clinicaltrials |
| NCT05059912 | CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03439501 | Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] | unknown | Phase 2 | 21 | Samsung Medical CenterOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT03146468 | Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation(NIVALLO) | unknown | Phase 2 | 14 | Melbourne HealthOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT05054426 | Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL(NHL-011) | unknown | Phase 3 | 488 | Peking Union Medical College HospitalOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT05054465 | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL(ITALLI001) | unknown | Phase 1 / Phase 2 | 48 | Israeli Medical AssociationOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT00293475 | Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 81 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04617704 | BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma | unknown | Early Phase 1 | 15 | Shanghai Changzheng HospitalOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT05020639 | A Study of TQB3820 in Patients With Hematological Malignancies | unknown | Phase 1 | 116 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 21, 2021 | clinicaltrials |
| NCT05049473 | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. | unknown | Phase 2 | 100 | PETHEMA FoundationOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT04862806 | Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL | unknown | N/A | 1,000 | Bnai Zion Medical CenterOTHER_GOV | 1 | Sep 17, 2021 | clinicaltrials |
| NCT04631458 | Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis(Mascot) | unknown | — | 40 | Royal Free Hospital NHS Foundation TrustOTHER | 0 | Sep 16, 2021 | clinicaltrials |
| NCT05047107 | Biology and Genetics of Smouldering Myeloma(COSMOS) | unknown | — | 500 | University College, LondonOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT04622956 | GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide | unknown | Phase 1 / Phase 2 | 47 | University of Sao Paulo General HospitalOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT04878822 | Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies | unknown | — | 300 | Ospedale di Circolo - Fondazione MacchiOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT03582254 | Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years(LOCALYSE) | unknown | N/A | 62 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT04826146 | Pediatric Validation of CONOX Monitor During Surgery | unknown | — | 65 | Patricio Gonzalez PizarroOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT05038696 | ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.(ALaCART) | unknown | Phase 1 | 40 | National University Hospital, SingaporeOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT05039658 | Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) | unknown | Phase 1 | 50 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 9, 2021 | clinicaltrials |
| NCT02899169 | Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)(APL16) | unknown | Phase 3 | 110 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT03476070 | Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS) | unknown | — | 236 | National University of SingaporeOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT04446741 | Molecular Diagnostic Platform for AML | unknown | — | 2,000 | PETHEMA FoundationOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT05006664 | Brentuximab Vedotin in Combination With CHEP in Patient With PTCL | unknown | Phase 2 | 33 | Czech Lymphoma Study GroupOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT03720457 | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT03798509 | Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT03943472 | BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma | unknown | Early Phase 1 | 10 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT05028478 | A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 164 | Curon Biopharmaceutical (Australia) Co Pty LtdINDUSTRY | 0 | Aug 31, 2021 | clinicaltrials |
| NCT05014100 | Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma | unknown | Phase 2 | 55 | Puyang Oilfield General HospitalOTHER | 0 | Aug 27, 2021 | clinicaltrials |
| NCT04736914 | Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT05021770 | Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma | unknown | Phase 1 / Phase 2 | 29 | Huiqiang HuangOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT02631239 | MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma | unknown | Phase 3 | 256 | Ruijin HospitalOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04687657 | Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia | unknown | Phase 1 | 20 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT05016063 | Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | unknown | Early Phase 1 | 32 | Xinqiao Hospital of ChongqingOTHER | 1 | Aug 23, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Oct 25, 2021source: clinicaltrials